Eric Rhodes on Horizon as CTO
This article was originally published in Scrip
Horizon Discovery, a provider of research tools to support the development of personalised medicines, has appointed Eric Rhodes chief technical officer of gene targeting. Mr Rhodes most recently served as business development director for Sigma-Aldrich Corp, and prior to that was vice-president of business development at Sangamo Biosciences. At Horizon, he will be the company's primary expert in human and mammalian gene targeting methods.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.